
Sign up to save your podcasts
Or


Amid the evolving treatment landscape for HER2-low breast cancer, many therapeutic challenges and limitations remain, resulting in unmet needs for our patients. Fortunately, developments in the therapeutic landscape can help address those unmet needs, and joining Dr. Charles Turck to share what’s on the horizon is Dr. Maryam Lustberg.
By ReachMD4.5
22 ratings
Amid the evolving treatment landscape for HER2-low breast cancer, many therapeutic challenges and limitations remain, resulting in unmet needs for our patients. Fortunately, developments in the therapeutic landscape can help address those unmet needs, and joining Dr. Charles Turck to share what’s on the horizon is Dr. Maryam Lustberg.